Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus
NCT03352674Phase 2Completed
- Sponsor
- Universitas Indonesia
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Universitas Indonesia. Primary endpoint: Incidence of immune response at 6 months. Started Sep 2016; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03352674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352674.